Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693726 · ClinicalTrials.gov registry record · Phase 4
Early Angiotensin II in the Emergency Department
A Phase 4 study of Septic Shock, sponsored by Brett A Faine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06693726: Recruiting Phase 4 study of Septic Shock, sponsored by Brett A Faine.
NCT06693726 is a Phase 4 study of Septic Shock that is actively recruiting participants, run by Brett A Faine. The registered enrollment target is 20 participants, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693726, a Phase 4 study of Septic Shock, is actively recruiting participants, sponsored by Brett A Faine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
Primary Outcome
Percentage of patients who provide informed consent and receive angiotensin II infusion in the emergency department
Conditions Studied
Interventions
- DRUG Angiotensin II Infusion
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 4 |
What NCT06693726 shows while recruiting
NCT06693726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II Infusion is the first listed.
NCT06693726 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06693726 about?
NCT06693726 is a clinical study titled "Early Angiotensin II in the Emergency Department". This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
What is the current status of trial NCT06693726?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-04-01. Estimated completion is 2026-11-30.
What conditions does trial NCT06693726 study?
This clinical trial studies the following conditions: Septic Shock.
What interventions are being tested in trial NCT06693726?
The interventions under investigation include: Angiotensin II Infusion (DRUG).
Who is sponsoring clinical trial NCT06693726?
This trial is sponsored by Brett A Faine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693726 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693726's enrollment target sits among peer trials
20 21st of 24 higher than 3 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Vasopressin for Septic Shock Pragmatic Trial
ACTIVE NOT RECRUITING · Phase 4
-
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
COMPLETED · Phase 4
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI